Report From the Sixth International Workshop on Waldenström's Macroglobulinemia
- 1 February 2011
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 69-73
- https://doi.org/10.3816/clml.2011.n.010
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Involvement of Ets Factor Spi-B and Id2 In Waldenström's MacroglobulinemiaBlood, 2010
- The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM)Blood, 2010
- Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom MacroglobulinemiaBlood, 2010
- Rituximab, Fludarabine and Alkylating Agents in Peripheral Neuropathies Related to IgM Monoclonal Gammopathy with Autoantibody Activity against Myelin-Associated-Glycoprotein : a Retrospective Study of 15 Patients.Blood, 2009
- International prognostic scoring system for Waldenström macroglobulinemiaBlood, 2009
- Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside AnalogsJournal of Clinical Oncology, 2009
- Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003